Distalmotion Raises $150M to Bring Surgical Robotics Beyond Hospitals

Distalmotion’s latest move signals a defining moment in the robotic-surgery market. With a fresh $150 million Series G, the Swiss-born company is doubling down on its bet that the next frontier for surgical robotics isn’t massive hospital systems—it’s the fast-growing network of ambulatory surgery centers across the U.S. The capital gives Distalmotion the fuel to accelerate commercial rollout of DEXTER, its soft-tissue surgical robot designed from day one to be simple, mobile, and economically viable in settings where traditional robotic platforms struggle to fit.

DEXTER represents a deliberate rethinking of robotic surgery. Rather than designing an all-encompassing, closed ecosystem, Distalmotion built a hybrid system: fully wristed, single-use instruments for precision; a portable footprint that slides into any operating room; and an open architecture that works with existing visualization tools and devices. The result is a workflow that keeps the surgeon bedside, allows seamless switching between laparoscopic and robotic techniques, and dramatically lowers operational barriers. The system has quietly built momentum, with nearly 3,000 patients treated across Europe and the U.S., supported by recent FDA clearance and product upgrades.

The financing also comes with a strategic heavyweight: longtime MedTech operator Chas McKhann joins as executive chairman. His résumé—scaling two public medical device companies through major growth and exits—signals that Distalmotion is preparing for a more assertive commercial phase. In a market long dominated by a single incumbent and now awakened by new challengers, Distalmotion is positioning itself as the platform built for the outpatient era: flexible, accessible, and primed for the shift toward minimally invasive care delivered outside traditional hospital walls.

Sources:
The Robot Report
Yahoo! Finance
Distalmotion

A.M.